Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study

Lancet

Volumn 349, Issue 9063, 1997, Pages 1429-1435

  Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; GLYCERYL TRINITRATE; HEPARIN; NITRATE;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0030918995     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)10452-9     Document Type: Article

References (29)

1. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
2. Falk E. Unstable angina pectoris with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-705.
3. Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410-14.
4. Miltenburg AJM van, Simoons ML, Veerhoek RJ, Bossuyt PMM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol 1995; 25: 1286-92.
5. Feyter PJ de, Brand M van den, Laarman GJ, Domburg R van, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927-36.
6. Feyter PJ de, Ruygrok PN. Coronary intervention: risk stratification and management of abrupt coronary occlusion. Eur Heart J 1995; 16: 97-103.
7. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
8. The RISC group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 3376: 827-30.
9. Coller BS, Peerscheke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
10. Simoons ML, Boer MJ de, Brand MJBM van den, et al. Randomised trial of a GP IIb-IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
11. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
12. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-86.
13. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated wtih recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
14. Landefeld LS, Cook EF, Hatley M. Identification and preliminary validation of predictors of major bleeding in hospitalised patients starting anticoagulant therapy. Am J Med 1987; 82: 703-13.
15. American College of Physicians Clinical Guideline: Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 403-06.
16. Klootwijk P, Langer A, Meij S, et al. Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. Eur Heart J 1996; 17: 689-98.
17. Klootwijk P, Meij S, van Es GA, et al. Comparison of usefulness of computer assisted continuous 48 hours 3-lead with 12-lead ECG-ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina. Eur Heart J 1996; 17: 689-98.
18. Lan KK, deMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
19. Topol EJ. Angiographic and clinical results of trials with glycoprotein IIb/IIIa blockers (IMPACT, EPILOG), presented at Congress European Society of Cardiology, Birmingham, 1996.
20. Tcheng JA, Lincoff AM. IMPACT-II. Integrelin (platelet IIb/IIIa receptor blocker) in coronary angioplasty: clinical and angiographic endpoints. Presented at the Congress European Society of Cardiology, Amsterdam, 1995.
21. King SB. 6 months angiographic and clinical follow-up of patients undergoing PTCA, treated with a platelet IIb/IIIa receptor blocker or placebo. Presented at European Congress of Cardiology, Birmingham, 1996.
22. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complication with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882-90.
23. Serruys PW, Jaegere P de, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
24. Fischman DL, Leon MB, Baim DS, et al. A randomised comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
25. Serruys PW, Emanuelsson H, Giessen W van der, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the BENESTENT-II Pilot study. Circulation 1996; 93: 412-22.
26. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-89.
27. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-34.
28. Ward SR, Lincoff M, Miller DP, et al. Clinical outcome is improved at 30 days, regardless of pre-treatment clinical and angiographic risk in patients receiving abciximab for angioplasty: results from the EPILOG study. Circulation (in press).
29. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629-35.